Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep;156(3):568-578.
doi: 10.1016/j.jaci.2025.05.030. Epub 2025 Jun 16.

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy

Erica V Lin  1 , Betania Arce  1 , Santiago Alvarez-Arango  2 , Melanie C Dispenza  3
Affiliations
Review

Current and future landscape of Bruton tyrosine kinase inhibitors in allergy

Erica V Lin et al. J Allergy Clin Immunol. 2025 Sep.

Abstract

As an essential component of the FcεRI pathway, Bruton tyrosine kinase (BTK) has become a target for treating allergic diseases. Several proof-of-concept studies using early-generation compounds such as ibrutinib and acalabrutinib demonstrated the ability of short courses of BTK inhibitors (BTKis) to reduce skin test responses to allergens, suppress basophil activation responses, and even completely prevent reactivity to allergenic food ingestion in humans. While early-generation BTKis do not have acceptable adverse effect profiles for chronic administration for nononcologic indications, newer compounds in development have higher selectivity for BTK and fewer adverse effects. In particular, remibrutinib has demonstrated remarkable efficacy and safety with chronic administration for chronic spontaneous urticaria and is poised to become the first BTKi approved in the United States for use in the allergy space. This review summarizes work using BTKis to treat allergic disorders, emphasizing safety and practical considerations for clinicians.

Keywords: Acalabrutinib; Bruton tyrosine kinase; anaphylaxis; chronic urticaria; food allergy.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement Supported by National Institutes of Health grant AI143965 (to M.C.D.) and an American Academy of Allergy, Asthma & Immunology (AAAAI) Foundation Faculty Development Award (to S.A.A.). Disclosure of potential conflict of interest: M. C. Dispenza has consulted and/or participated on advisory boards for Aditum Bio, ALK, Allakos, Blueprint Medicines, Guidepoint, GLG, Melinta Therapeutics, and Nurix Therapeutics; and has received funding from AstraZeneca. The rest of the authors declare that they have no relevant conflicts of interest.

References

    1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8. - PubMed
    1. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 1993;72(2):279–90. - PubMed
    1. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, Flinter F, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361(6409):226–33. - PubMed
    1. Khan WN. Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase. Immunol Res. 2001;23(2–3):147–56. - PubMed
    1. Dispenza MC, Krier-Burris RA, Chhiba KD, Undem BJ, Robida PA, Bochner BS. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J Clin Invest. 2020;130(9):4759–70. - PMC - PubMed

MeSH terms